Daniel J. Blackman

Showing 1-7 of 7 articles

Interventions for valvular disease

Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients

Meredith I, Dumonteil N, Blackman D, Tchétché D, Walters D, Hildick-Smith D, Manoharan G, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Feldman T, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01024

Interventions for valvular disease

Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort

Dumonteil N, Meredith I, Blackman D, Tchétché D, Hildick-Smith D, Spence M, Walters D, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Houle V, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01025

Coronary interventions

Post-procedural myocardial infarction following surgical aortic valve replacement and transcatheter aortic valve implantation

Dobson L, Musa T, Uddin A, Fairbairn T, Swoboda P, Ripley D, Garg P, Evans B, Malkin C, Blackman D, Plein S, Greenwood J

June 2, 2017 | 10.4244/EIJ-D-16-00558

Interventions for valvular disease

Impact of left ventricular function and transaortic gradient on outcomes from transcatheter aortic valve implantation: data from the UK TAVI Registry

Malkin C, Long W, Baxter P, Gale C, Wendler O, Monaghan M, Thomas M, Ludman P, De Belder M, Cunningham A, Moat N, Blackman D

February 19, 2016 | 10.4244/EIJY14M12_12

Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population

Shelton R, Eftychiou C, Somers K, Liu A, Burton-Wood N, Anderson M, Makri L, Blaxill J, McLenachan J, Wheatcroft S, Greenwood J, Blackman D

May 21, 2013 | 10.4244/EIJV9I1A17

Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design

Kelly D, McCann G, Blackman D, Curzen N, Dalby M, Greenwood J, Fairbrother K, Shipley L, Kelion A, Heatherington S, Khan J, Nazir S, Alahmar A, Flather M, Swanton H, Schofield P, Gunning M, Hall R, Gershlick A

February 22, 2013 | 10.4244/EIJV8I10A183

Complications of transcatheter aortic valve implantation: avoidance and management

Hildick-Smith D, Redwood S, Mullen M, Thomas M, Kovac J, Brecker S, Trivedi U, Young C, Hutchinson N, MacCarthy P, Prendergast B, De Belder M, Monaghan M, Blackman D, Baumbach A, Manoharan G, Moat N

September 30, 2011 | 10.4244/EIJV7I5A99

Latest news

NEW ISSUE

LM revascularisation, annulus rupture, risk stratification, renal denervation

May 20, 2020

NEW

Ahead of print: Transcatheter treatment of multivalvular heart disease

Cardioband after placement of 17 screws before and after

May 27, 2020

Editorial

Balancing risks and benefits of LM revascularisation strategies in CKD patients

Gennaro Giustino

May 27, 2020

Trials Book

Last Update: CULPRIT, NOBEL, IVUS-XPL, SAFARI-STEMI

(supported by Biotronik)

May 14, 2020

Guidance Papers

Guidelines, consensus & position papers

May 14, 2019

Editorial

Contained annulus ruptures – the price to pay for optimal haemodynamic results?

Fabian Nietlispach

May 27, 2020

JAA

This week's JAA's: Right pulmonary artery to left atrium fistula, BRS in high-risk patients

Daniel J. Blackman

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke